Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy

Journal of Urology

Volumn 160, Issue 4, 1998, Pages 1387-1391

  Cher, Michael L ^a   Bianco Jr , Fernando J ^a   Lam, John S ^a   Davis, Lawrence P ^a   Grignon, David J ^a   Sakr, Wael A ^a   Banerjee, Mousumi ^a   Pontes, J Edson ^a   Wood Jr , David P ^a  

^a NONE

Author keywords

Bone and bones; Prostate specific antigen; Prostatectomy; Radionuclide imaging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0032323478     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62545-X     Document Type: Article

References (19)

1. Pound, C. R., Partin, A. W., Epstein, J. I. and Walsh, P. C.: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. N. Amer., 24: 395, 1997.
2. Sakr, W. A., Grignon, D. J., Visscher, D. W., Wolman, S. R. and Crissman, J. D.: Evaluating the radical prostatectomy specimen. I: A protocol for establishing prognostic parameters and harvesting fresh tissue samples. J. Urol. Path., 3-4: 377, 1995.
3. Sakr, W. A., Wheeler, T. M., Blute, M., Bodo, M., Calle-Rodrigue, R., Henson, D. E., Mostofi, F. K., Seiffert, J., Wojno, K. and Zincke, H.: Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer, 78: 366, 1996.
4. Osmond, J. D., Pendergrass, H. P. and Potsaid, M. S.: Accuracy of 99mTC-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases. AJR, Radium Ther. Nucl. Med., 125: 972, 1975.
5. Schaffer, D. L. and Pendergrass, H. P.: Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology, 121: 431, 1976.
6. Oesterling, J. E., Martin, S. K., Bergstralh, E. J. and Lowe, F. C.: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A., 269: 57, 1993.
7. Lee, C. T. and Oesterling, J. E.: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol. Clin. N. Amer., 24: 389, 1997.
8. Chybowski, F. M., Larson Keller, J. J., Bergstralh, E. J. and Oesterling, J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol., 145: 313, 1991.
9. Ferguson, J. K. and Oesterling, J. E.: Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy. Urol. Clin. N. Amer., 21: 677, 1994.
10. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142: 1011, 1989.
11. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
12. Miller, P. D., Eardley, I. and Kirby, R. S.: Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Brit. J. Urol., 70: 295, 1992.
13. Terris, M. K., Klonecke, A. S., McDougall, I. R. and Stamey, T. A.: Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J. Nucl. Med., 32: 1713, 1991.
14. Partin, A. W., Pearson, J. D., Landis, P. K., Carter, H. B., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 43: 649, 1994.
15. Oefelein, M. G., Smith, N., Carter, M., Dalton, D. and Schaeffer, A.: The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J. Urol., 154: 2128, 1995.
16. Goldrath, D. E. and Messing, E. M.: Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. J. Urol., 142: 1082, 1989.
17. Sodee, D. B., Conant, R., Chalfant, M., Miron, S., Klein, E., Bahnson, R., Spirnak, J. P., Carlin, B., Bellon, E. M. and Rogers, B.: Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin. Nucl. Med., 21: 759, 1996.
18. Chengazi, V. U., Feneley, M. R., Ellison, D., Stalteri, M., Granowski, A., Granowska, M., Nimmon, C. C., Mather, S. J., Kirby, R. S. and Britton, K. E.: Imaging prostate cancer with technetium-99m-7E11-C5.3 (CYT-351). J. Nucl. Med., 38: 675, 1997.
19. Wood, D. P., Jr. and Banerjee, M.: Presence of circulating prostate cells in the bone-marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J. Clin. Oncol., 15: 3451, 1997.